BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
73.64
-1.12 (-1.50%)
At close: Dec 5, 2025, 4:00 PM EST
74.99
+1.35 (1.83%)
After-hours: Dec 5, 2025, 7:22 PM EST
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for BridgeBio Pharma stock have an average target of 74.79, with a low estimate of 49 and a high estimate of 110. The average target predicts an increase of 1.56% from the current stock price of 73.64.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BridgeBio Pharma stock from 19 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 9 | 9 | 9 |
| Buy | 9 | 9 | 9 | 9 | 10 | 10 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 18 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $76 → $84 | Buy | Maintains | $76 → $84 | +14.07% | Nov 11, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $76 → $77 | Buy | Maintains | $76 → $77 | +4.56% | Nov 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +22.22% | Nov 3, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $55 → $100 | Strong Buy | Maintains | $55 → $100 | +35.80% | Oct 31, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $60 → $95 | Strong Buy | Maintains | $60 → $95 | +29.01% | Oct 30, 2025 |
Financial Forecast
Revenue This Year
506.91M
from 221.90M
Increased by 128.44%
Revenue Next Year
892.89M
from 506.91M
Increased by 76.14%
EPS This Year
-3.55
from -2.88
EPS Next Year
-1.86
from -3.55
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 593.7M | 1.3B | ||||
| Avg | 506.9M | 892.9M | ||||
| Low | 447.3M | 568.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 167.5% | 156.7% | ||||
| Avg | 128.4% | 76.1% | ||||
| Low | 101.6% | 12.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.19 | -0.71 | ||||
| Avg | -3.55 | -1.86 | ||||
| Low | -3.59 | -2.79 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.